> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Grants MediciNova Fast Track for Multiple Sclerosis Drug
- URL: https://www.fdaweb.com/fda-grants-medicinova-fast-track-for-multiple-sclerosis-drug/
- Published: 2016-03-22T12:00:00.000Z
- Updated: 2026-09-14T20:50:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135155

> FDA has granted MediciNova a fast track designation for MN-166 (ibudilast) and its use in treating patients with progressive multiple sclerosis. MN-166 has been marketed in Japan and Korea since 1989 to treat post-stroke complications and bronchial asthma. MediciNova licensed the drug from Kyorin Pharmaceutical for potential utility in relapse-remitting multiple sclerosis.  
>  
> The company describes the therapy is a first-in-class, orally bioavailable, small molecule phosphodiesterase (PDE) -4 and -10 inhibitor and a macrophage migration inhibitory factor inhibitor that suppresses pro-inflammatory cytokines and promotes neurotrophic factors. “It attenuates activated glia cells, which play a major role in certain neurological conditions,” MedicNova says. Ibudilast's anti-neuroinflammatory and neuroprotective actions have been demonstrated in preclinical and clinical study results, it says.